Kenmare Bio

Kenmare Bio is an early-stage biotechnology company focused on developing next-generation therapies for complement-mediated diseases. Headquartered in Cambridge, Massachusetts, and backed by Atlas Venture, the company leverages deep expertise in innate immunity to engineer biologics that precisely modulate the complement system. Its primary focus is on treating geographic atrophy, a late-stage form of age-related macular degeneration, by addressing the limitations of first-generation complement inhibitors. Kenmare Bio aims to provide superior clinical outcomes through optimized tissue penetration and target engagement in high-unmet-need inflammatory and degenerative conditions.